Cytotoxicity is the quality of being toxic to cells. Examples of toxic agents are an immune cell or some types of venom, e.g. from the puff adder (Bitis arietans) or brown recluse spider (Loxosceles reclusa).
Treating cells with the cytotoxic compound can result in a variety of cell fates. The cells may undergo necrosis, in which they lose membrane integrity and die rapidly as a result of cell lysis. The cells can stop actively growing and dividing (a decrease in cell viability), or the cells can activate a genetic program of controlled cell death (apoptosis).
Cells undergoing necrosis typically exhibit rapid swelling, lose membrane integrity, shut down metabolism, and release their contents into the environment. Cells that undergo rapid necrosis in vitro do not have sufficient time or energy to activate apoptotic machinery and will not express apoptotic markers. Apoptosis is characterized by well defined cytological and molecular events including a change in the refractive index of the cell, cytoplasmic shrinkage, nuclear condensation and cleavage of DNA into regularly sized fragments. Cells in culture that are undergoing apoptosis eventually undergo secondary necrosis. They will shut down metabolism, lose membrane integrity and lyse.
Cytotoxicity assays are widely used by the pharmaceutical industry to screen for cytotoxicity in compound libraries. Researchers can either look for cytotoxic compounds, if they are interested in developing a therapeutic that targets rapidly dividing cancer cells, for instance; or they can screen "hits" from initial high-throughput drug screens for unwanted cytotoxic effects before investing in their development as a pharmaceutical.
Assessing cell membrane integrity is one of the most common ways to measure cell viability and cytotoxic effects. Compounds that have cytotoxic effects often compromise cell membrane integrity. Vital dyes, such as trypan blue or propidium iodide are normally excluded from the inside of healthy cells; however, if the cell membrane has been compromised, they freely cross the membrane and stain intracellular components. Alternatively, membrane integrity can be assessed by monitoring the passage of substances that are normally sequestered inside cells to the outside. One molecule, lactate dehydrogenase (LDH), is commonly measured using LDH assay. LDH reduces NAD to NADH which elicits a colour change by interaction with a specific probe. Protease biomarkers have been identified that allow researchers to measure relative numbers of live and dead cells within the same cell population. The live-cell protease is only active in cells that have a healthy cell membrane, and loses activity once the cell is compromised and the protease is exposed to the external environment. The dead-cell protease cannot cross the cell membrane, and can only be measured in culture media after cells have lost their membrane integrity.
Cytotoxicity can also be monitored using the 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) or with 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT), which yields a water-soluble product, or the MTS assay. This assay measures the reducing potential of the cell using a colorimetric reaction. Viable cells will reduce the MTS reagent to a colored formazan product. A similar redox-based assay has also been developed using the fluorescent dye, resazurin. In addition to using dyes to indicate the redox potential of cells in order to monitor their viability, researchers have developed assays that use ATP content as a marker of viability. Such ATP-based assays include bioluminescent assays in which ATP is the limiting reagent for the luciferase reaction.
Cytotoxicity can also be measured by the sulforhodamine B (SRB) assay, WST assay and clonogenic assay.
Suitable assays can be combined and performed sequentially on the same cells in order to reduce assay-specific false positive or false negative results. A possible combination is LDH-XTT-NR (Neutral red assay)-SRB which is also available in a kit format.
A label-free approach to follow the cytotoxic response of adherent animal cells in real-time is based on electric impedance measurements when the cells are grown on gold-film electrodes. This technology is referred to as electric cell-substrate impedance sensing (ECIS). Label-free real-time techniques provide the kinetics of the cytotoxic response rather than just a snapshot like many colorimetric endpoint assays.
A highly important topic is the prediction of cytotoxicity of chemical compounds based on previous measurements, i.e. in-silico testing. For this purpose many QSAR and virtual screening methods have been suggested. An independent comparison of these methods has been done within the "Toxicology in the 21st century" project.
In Chemotherapy, cytotoxic drugs are used for their interference in various ways with cell division. The drugs cannot distinguish between normal and malignant cells, but inhibit the process of cell division, with the objective to kill the cancer before the host.
Antibody-dependent cell-mediated cytotoxicity (ADCC) describes the cell-killing ability of certain lymphocytes, which requires the target cell being marked by an antibody. Lymphocyte-mediated cytotoxicity, on the other hand, does not have to be mediated by antibodies; nor does complement-dependent cytotoxicity (CDC), which is mediated by the complement system.
Three groups of cytotoxic lymphocytes are distinguished:
- Cytotoxic T cells
- Natural killer cells
- Natural killer T cells
- Antireticular Cytotoxic Serum
- Host-pathogen interface
- Membrane vesicle trafficking
- Snake toxins
- Riss TL, Moravec RA; Moravec (February 2004). "Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays". Assay Drug Dev Technol. 2 (1): 51–62. doi:10.1089/154065804322966315. PMID 15090210.
- Decker T, Lohmann-Matthes ML; Lohmann-Matthes (November 1988). "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity". J. Immunol. Methods. 115 (1): 61–9. doi:10.1016/0022-1759(88)90310-9. PMID 3192948.
- Niles AL, Moravec RA, Eric Hesselberth P, Scurria MA, Daily WJ, Riss TL (July 2007). "A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers". Anal. Biochem. 366 (2): 197–206. doi:10.1016/j.ab.2007.04.007. PMID 17512890.
- Fan F, Wood KV; Wood (February 2007). "Bioluminescent assays for high-throughput screening". Assay Drug Dev Technol. 5 (1): 127–36. doi:10.1089/adt.2006.053. PMID 17355205. S2CID 10261888.
- Dearden, J. C. (2003). "In silico prediction of drug toxicity". Journal of Computer-aided Molecular Design. 17 (2–4): 119–27. Bibcode:2003JCAMD..17..119D. doi:10.1023/A:1025361621494. PMID 13677480. S2CID 21518449.
- "Toxicology in the 21st century Data Challenge" https://tripod.nih.gov/tox21/challenge/leaderboard.jsp
- Priestman, T. J. (1989). "Cancer Chemotherapy: an Introduction". doi:10.1007/978-1-4471-1686-8. Cite journal requires
- "How Is Chemotherapy Used to Treat Cancer?". www.cancer.org. Retrieved 2021-06-28.